Piper Sandler raised the firm’s price target on Xeris Biopharma (XERS) to $4 from $3 and keeps a Neutral rating on the shares. The firm notes Xeris reported a Q4 net loss per share of (3c) on total revenues of $60.1M, compared to Street estimates of (6c) and $58.1M, respectively. Management is guiding to 2025 total revenue of $255M-$275M, implying annual growth of about 35% versus 2024 at the midpoint.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS:
- Xeris Pharmaceuticals: Strong Growth Potential and Financial Stability Justify Buy Rating
- Xeris Biopharma price target raised to $8 from $6.60 at H.C. Wainwright
- Xeris Biopharma Reports Record Revenue and Strong 2025 Outlook
- Xeris Biopharma files $250M mixed securities shelf
- Xeris Biopharma reports Q4 EPS (3c), consensus (2c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue